TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Absolute change in the SRS-22r total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of catheter-associated blood stream infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in systemic immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in systemic adipose inflammation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with a response for Early Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Recruited to the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Perceived the Intervention as Useful
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major Adverse Cardiac Event (MACE) occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Levofloxacin serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in intensity and frequency of GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in GERD questionnaire (GERD-Q) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cabotegravir Concentration in Blood Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cabotegravir Concentration in Vaginal Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cabotegravir Concentration in Cervical Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of brain biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of brain biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Complete Response (CR) During Acute Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Response (CR) During Delayed Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Response (CR) During Overall Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incretin Effect (% of Insulin Secreted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Liver functional restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time for first demand of rescue analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of acute child malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of child acute malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compliance to treatment of acute malnutrition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse Events Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Total Daily Area Under the Plasma Concentration-time Profile (AUC0-24,ss) of Aztreonam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Aztreonam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Daily Area Under the Plasma Concentration-time Profile (AUC0-24,ss) of Avibactam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Avibactam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of swallowing function safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified nine hole peg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four square step test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Clinical Test of Sensory Integration and Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of yttrium-90 (90Y) M5A anti-CEA antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication error
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days to ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transversus Abdominis thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Plasma Concentration for Z-215
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2: Terminal Elimination Half-life for Z-215
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Z-215
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient activity and participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lumbar Spine Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine Protein Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Secretion of Gut Hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post operative depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of reaching the standard arrival-to-groin puncture time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: median relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of cell lysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Joint-Specific Multidimensional Assessment of Pain (J-MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with knee condition (SKIP)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle taurine content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Tumor size volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: S100β/HIA score in concussion management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Markers of long-term brain cell damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percent screening positive for depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specialty mental health visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: antidepressant medication possession ratio
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Achieved a Minimum Adapted ACR Pediatric 30 Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Canakinumab Treatment Who Were Able to Taper Corticosteroids Successfully
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma glucose concentration of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine glucose concentration of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma pharmacokinetic parameters of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of essential nutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in psychosocial functions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hamilton Depression Rating Scale-24
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Daily blood glucose profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial concentration of GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: prosthesis related infections
Endpoint domain: Adverse events/effects
Primary endpoint: Value of screening for Fabry's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemodynamic 4D flow profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total radioactivity (TRA) in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) for [14C]-AR882
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life (t1/2) for [14C]-AR882
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Lactobacillus reuteri
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak hetrombopag plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the plasma hetrombopag concentration vs time curve (AUC0-120)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma hetrombopag concentration vs time curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIBIC+ Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Central Retinal Lesion Thickness (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Best Correct Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Nipple pain change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nipple sore change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nipple trauma change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Readmissions for chest pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Midterm mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in body mass index (BMI) z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cavity Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in transcranial regional cerebral oxygenation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neural activation during social reward processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Zarit Burden Interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetics of AZD2281
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to diagnostic colposcopy appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of abnormal laboratory findings
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of abnormal electrocardiogram findings
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of abnormal vital signs findings
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC) for plasma AR882
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum plasma concentration (Tmax) for AR882
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Sexual Partners
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Circumference measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gambling Symptoms Assessment Scale (GSAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Financial Well-Being Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mental Help Seeking Intention Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titer (GMT) of neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects achieving a serum neutralizing antibody titer of 1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events (AE) or serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Numerical Pain Rating Scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: readiness to change
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Core temperature of <35.0°C at reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent change from baseline in insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in services consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients with complete and/or partial remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-related, Non-hematologic Grade ≥ 3 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Obstructive Apnea and Hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in voltage at pacemaker lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects reaching EAS LDL-C target goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Iowa Level of Assistance Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hospital for Special Surgery Knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 meter walk speed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fecal Microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absence of clinically significant trauma to skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Seroconversion for poliovirus type 1, 2 and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence and severity of acute abdominal pancreatitis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of local/systemic adverse events after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of the volunteers with LST>0 protected against CL (absence of a lesion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage Change in Psoriasis Scalp Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in total fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: occurrence of cough
Endpoint domain: Adverse events/effects
Primary endpoint: Delta wave miss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spindle miss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Antimicrobial concentration of catheter-lock solutions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osseous modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DPI Responder Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Tinnitus Handicap Inventory (THI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for Immunosuppressive drug therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean change in extrapyramidal symptoms measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decisional Conflict Scale (DCS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Somatic mutation identification in T-cell and NK lymphoma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: admission to intensive care units
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adverse events related to the study
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of Paclitaxel-induced peripheral neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in post-dose residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Differences (SPID) Over 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical symptoms of asthma and allergic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Image Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in ACT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Break up Time With Fluorescein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants achieving dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants achieving Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion with a major adverse kidney event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Numerical Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's Rating of Physician's Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in number of migraine days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of point-of-care ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Thymic Stromal Lymphopoietin (TSLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of IL-33 Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neumeric pain rating scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemokine receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Femur length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release profile of Ondansetron Pulsatile Release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hot Flash Related Daily Interference Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Presence and distribution of amyloid deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Neuropathic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes